**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Christoph Kimmich, Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.

**Main Body of the Abstract**
Introduction:  Subcutaneous fat aspiration is a minimally-invasive screening tool utilized by amyloidosis centers to screen for systemic amyloidosis (SA). Aspirates are typically performed at only at centers.
Methods: Sensitivity and specificity for consecutive fat aspirates performed between November 2020 and January 2024 at the amyloidosis clinic in Oldenburg (OL) were evaluated at the amyloidosis center Heidelberg (HD). Samples were sent within a sealed syringe via courier from OL to HD accompanied by an informed consent form. For sensitivity analysis patients with SA proven by either histopathology or scintigraphy and for specificity analysis patients with clinically certain exclusion of SA were chosen. Aspiration and analysis were performed according to (1).
Results: A total of 16/25 probes from patients with proven SA and 14/82 probes from patients with suspected SA (see Table) were classified as positive. All positive screening probes originated from patients with an underlying monoclonal gammopathy (MG) and in eleven of the cases could be confirmed as systemic light-chain (AL) amyloidosis. In four patients with negative screening probes amyloid was detected in another biopsy.
An overall sensitivity of 68% (25/40) and a specificity of 100% (11/11) were achieved. Additionally, 3/56 probes from patients with MG and clinically possible SA showed amyloid deposits.
For subtypes, sensitivities were: systemic AL 78% (25/32), systemic wild-type transthyretin 0% (0/4) and systemic SAA 50% (2/4). Sensitivity was 90% (9/10) in females (only AL) and 60% (18/30) in males.
Conclusion: Externally performed fat aspirates analyzed at an experienced center yield a good sensitivity for systemic AL.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Christoph Kimmich, Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.

**Main Body of the Abstract**
**Introduction:**  Subcutaneous fat aspiration is a minimally-invasive screening tool utilized by amyloidosis centers to screen for systemic amyloidosis (SA). Aspirates are typically performed at only at centers.
**Methods**: Sensitivity and specificity for consecutive fat aspirates performed between November 2020 and January 2024 at the amyloidosis clinic in Oldenburg (OL) were evaluated at the amyloidosis center Heidelberg (HD). Samples were sent within a sealed syringe via courier from OL to HD accompanied by an informed consent form. For sensitivity analysis patients with SA proven by either histopathology or scintigraphy and for specificity analysis patients with clinically certain exclusion of SA were chosen. Aspiration and analysis were performed according to (1).
**Results:** A total of 16/25 probes from patients with proven SA and 14/82 probes from patients with suspected SA (see Table) were classified as positive. All positive screening probes originated from patients with an underlying monoclonal gammopathy (MG) and in eleven of the cases could be confirmed as systemic light-chain (AL) amyloidosis. In four patients with negative screening probes amyloid was detected in another biopsy.
An overall sensitivity of 68% (25/40) and a specificity of 100% (11/11) were achieved. Additionally, 3/56 probes from patients with MG and clinically possible SA showed amyloid deposits.
For subtypes, sensitivities were: systemic AL 78% (25/32), systemic wild-type transthyretin 0% (0/4) and systemic SAA 50% (2/4). Sensitivity was 90% (9/10) in females (only AL) and 60% (18/30) in males.
**Conclusion**: Externally performed fat aspirates analyzed at an experienced center yield a good sensitivity for systemic AL.



Fat aspiration for minimally-invasive amyloidosis screening from an external amyloidosis clinic PA72 (#382)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.